158 related articles for article (PubMed ID: 37019411)
21. Upregulation of TRIB2 by Wnt/β-catenin activation in BRAF
Wang N; Wen J; Ren W; Wu Y; Deng C
Cancer Chemother Pharmacol; 2021 Jul; 88(1):155-164. PubMed ID: 33860836
[TBL] [Abstract][Full Text] [Related]
22. Papillary thyroid carcinoma with nodular fasciitis-like stroma: a rare variant.
Parkhi M; Chatterjee D; Bardia A; Kanaval AJ; Sood A; Saikia UN; Bansal N
Autops Case Rep; 2021; 11():e2021320. PubMed ID: 34458186
[TBL] [Abstract][Full Text] [Related]
23. Pancreatic metastasis arising from a BRAF(V600E)-positive papillary thyroid cancer: the role of endoscopic ultrasound-guided biopsy and response to sorafenib therapy.
Alzahrani AS; AlQaraawi A; Al Sohaibani F; Almanea H; Abalkhail H
Thyroid; 2012 May; 22(5):536-41. PubMed ID: 22435913
[TBL] [Abstract][Full Text] [Related]
24. High expression and localization of β-catenin and epidermal growth factor receptor identify high risk papillary thyroid carcinoma patients.
Išić Denčić T; Bartolome A; Šelemetjev S; Đorić I; Tatić S; Živaljević V; Cvejić D
Exp Mol Pathol; 2018 Oct; 105(2):181-189. PubMed ID: 30077672
[TBL] [Abstract][Full Text] [Related]
25. Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features: Epidemiology and Long-Term Outcomes in a Strictly Defined Cohort.
Chung R; Guan H; Ponchiardi C; Cerda S; Marwaha N; Yilmaz OH; Pinjic E; McAneny D; Lee SL; Drake FT
Thyroid; 2021 Jan; 31(1):68-75. PubMed ID: 32539676
[No Abstract] [Full Text] [Related]
26. PROGNOSTIC VALUE OF LYMPH NODE UPTAKE ON PRETREATMENT F-18 FDG PET/CT IN PATIENTS WITH N1B PAPILLARY THYROID CARCINOMA.
Lee CH; Lee SW; Son SH; Hong CM; Jeong JH; Jeong SY; Ahn BC; Lee J
Endocr Pract; 2019 Aug; 25(8):787-793. PubMed ID: 31013158
[No Abstract] [Full Text] [Related]
27. Papillary thyroid carcinoma with nodular fasciitis-like stroma and β-catenin gene mutations: report of a recurrent case.
Zhou L; Shi L; Jiang Z; Xie L
Int J Clin Exp Pathol; 2018; 11(5):2879-2883. PubMed ID: 31938411
[TBL] [Abstract][Full Text] [Related]
28. Novel pathogenic alterations in pediatric and adult desmoid-type fibromatosis - A systematic analysis of 204 cases.
Trautmann M; Rehkämper J; Gevensleben H; Becker J; Wardelmann E; Hartmann W; Grünewald I; Huss S
Sci Rep; 2020 Feb; 10(1):3368. PubMed ID: 32099073
[TBL] [Abstract][Full Text] [Related]
29. Differences in the Recurrence and Survival of Patients with Symptomatic and Asymptomatic Papillary Thyroid Carcinoma: An Observational Study of 11,265 Person-Years of Follow-Up.
Kim SH; Roh JL; Gong G; Cho KJ; Choi SH; Nam SY; Kim SY
Thyroid; 2016 Oct; 26(10):1472-1479. PubMed ID: 27457917
[TBL] [Abstract][Full Text] [Related]
30. Case report: exceptionally rapid growth character of hobnail variant of papillary thyroid carcinoma: a report of four cases.
Ito Y; Hirokawa M; Hayashi T; Ota H; Oshita M; Kihara M; Miya A; Miyauchi A
Endocr J; 2020 Oct; 67(10):1047-1053. PubMed ID: 32554948
[TBL] [Abstract][Full Text] [Related]
31. The role of BRAF V600E mutation as a potential marker for prognostic stratification of papillary thyroid carcinoma: a long-term follow-up study.
Daliri M; Abbaszadegan MR; Bahar MM; Arabi A; Yadollahi M; Ghafari A; Taghehchian N; Zakavi SR
Endocr Res; 2014; 39(4):189-93. PubMed ID: 24679337
[TBL] [Abstract][Full Text] [Related]
32. Thyroid Cancer Identified After Positron Emission Tomography (PET) Shows Aggressive Histopathology.
Beck T; Zhang N; Shah A; Khoncarly S; McHenry C; Jin J
J Surg Res; 2021 Apr; 260():245-250. PubMed ID: 33360690
[TBL] [Abstract][Full Text] [Related]
33. ENHANCED BETA-CATENIN EXPRESSION IS ASSOCIATED WITH RECURRENCE OF PAPILLARY THYROID CARCINOMA.
Kordestani Z; Sanjari M; Safavi M; Mashrouteh M; Asadikaram G; Abadi MFS; Mirzazadeh A
Endocr Pract; 2018 May; 24(5):411-418. PubMed ID: 29498921
[TBL] [Abstract][Full Text] [Related]
34. Papillary and follicular variant of papillary carcinoma of the thyroid: Initial presentation and response to therapy.
Burningham AR; Krishnan J; Davidson BJ; Ringel MD; Burman KD
Otolaryngol Head Neck Surg; 2005 Jun; 132(6):840-4. PubMed ID: 15944551
[TBL] [Abstract][Full Text] [Related]
35. Epidermal growth factor receptor overexpression is a marker for adverse pathologic features in papillary thyroid carcinoma.
Fisher KE; Jani JC; Fisher SB; Foulks C; Hill CE; Weber CJ; Cohen C; Sharma J
J Surg Res; 2013 Nov; 185(1):217-24. PubMed ID: 23746767
[TBL] [Abstract][Full Text] [Related]
36. BRAFV600E Mutation Does Not Significantly Affect the Efficacy of Radioiodine Therapy in Patients With Papillary Thyroid Carcinoma Without Known Distant Metastases.
Shen G; Kou Y; Liu B; Huang R; Kuang A
Clin Nucl Med; 2018 Jul; 43(7):e215-e219. PubMed ID: 29762246
[TBL] [Abstract][Full Text] [Related]
37. BRAF(V600E) Mutation is Associated with Decreased Disease-Free Survival in Papillary Thyroid Cancer.
Fraser S; Go C; Aniss A; Sidhu S; Delbridge L; Learoyd D; Clifton-Bligh R; Tacon L; Tsang V; Robinson B; Gill AJ; Sywak M
World J Surg; 2016 Jul; 40(7):1618-24. PubMed ID: 27138882
[TBL] [Abstract][Full Text] [Related]
38. Radioactive iodine does not improve overall survival for patients with aggressive variants of papillary thyroid carcinoma less than 2 cm.
Holoubek SA; MacKinney EC; Khokar AM; Kuchta KM; Winchester DJ; Prinz RA; Moo-Young TA
Surgery; 2022 Jan; 171(1):203-211. PubMed ID: 34384604
[TBL] [Abstract][Full Text] [Related]
39. Outcomes of Papillary Thyroid Microcarcinoma Presenting with Palpable Lateral Lymphadenopathy.
Papachristos A; Do K; Tsang VH; Sywak M; Gill AJ; Sidhu S; Clifton-Bligh RJ; Glover A; Gild ML
Thyroid; 2022 Sep; 32(9):1086-1093. PubMed ID: 35703333
[No Abstract] [Full Text] [Related]
40. GADD45B Transcript Is a Prognostic Marker in Papillary Thyroid Carcinoma Patients Treated With Total Thyroidectomy and Radioiodine Therapy.
Barros-Filho MC; de Mello JBH; Marchi FA; Pinto CAL; da Silva IC; Damasceno PKF; Soares MBP; Kowalski LP; Rogatto SR
Front Endocrinol (Lausanne); 2020; 11():269. PubMed ID: 32425887
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
